PDEs as drug targets

PDEs as drug targets

As selected PDE family members are critical regulators of cyclic AMP signaling, they make terrific targets for designing new medicines. For example, PDE4 inhibitors such as Otezla® (apremilast) and Daxas® (roflumilast) exert their effects by reducing cyclic AMP breakdown and enhancing the cyclic AMP signal.

To date, no PDE4 activators have been discovered but it is possible that they could also be utilised as therapeutics by accelerating cAMP breakdown and reducing the cAMP signaling.

An ambitious, vibrant, growing, customer-centric company

get in touch